Aminopeptidase N: Clinical Trials Continue to Generate New Insights in Therapeutics
Advances in immunophenotyping diagnosis processes to garner information about leukemia or lymphoma and its plausible response to certain treatments has contributed towards clinical study and trials for aminopeptidase N (CD13). CD13 is extensively used as pan-myeloid marker to diagnose myeloid leukemia. In its recently added report titled, 'Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Pipeline Review, H1 2018', Market Research Hub...
View full press release